Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 15:78:102927.
doi: 10.1016/j.eclinm.2024.102927. eCollection 2024 Dec.

International PCOS guideline clinical research priorities roadmap: a co-designed approach aligned with end-user priorities in a neglected women's health condition

Collaborators, Affiliations

International PCOS guideline clinical research priorities roadmap: a co-designed approach aligned with end-user priorities in a neglected women's health condition

H J Teede et al. EClinicalMedicine. .

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common endocrinopathy with significant reproductive, metabolic, and psychological complications. Consensus on PCOS clinical research priorities across end-users is fundamental and necessitates a robust co-development of a clinical research roadmap to guide international research efforts.

Methods: A multistage process included: i) international surveys of women and healthcare providers to identify research priorities and unmet needs; ii) interrogation of systematic reviews conducted for the International PCOS Guideline to identify research gaps; iii) International PCOS Guideline Network consensus generated clinical research roadmap; and iv) international peer review for external validation.

Findings: A codesigned survey engaging 1278 women with PCOS and 1474 healthcare providers found general concordance on research priorities. International PCOS Guideline development processes identified gaps in the literature and coproduced over 150 research priorities throughout the women's life course, affirmed in international peer review. Key themes included: 1) Optimizing PCOS diagnosis; understanding natural history across diverse populations and life stages; detecting and preventing complications, and integrating and interrogating large data assets; 2) developing evidence-based resources, exploring optimal modes for information provision and models of care; 3) exploring effective lifestyle and weight management strategies; minimising weight stigma; 4) exploring intervention effects (including treatment efficacy, safety, cost-effectiveness, and long-term follow-up) on diverse features of PCOS across subgroups; and 5) optimising preconception care and fertility treatments in PCOS.

Interpretation: This rigorously coproduced International PCOS Guideline clinical research roadmap addresses stakeholder priorities to guide future clinical research in this common yet neglected condition. The roadmap complements the established PCOS Core Outcome Set to enhance research quality, and tackles evidence-practice gaps to improve health outcomes for women with PCOS throughout their life course.

Funding: The survey, International PCOS Guideline Network and 2018 and 2023 International PCOS Guidelines were funded by the Australian National Health and Medical Research Council (NHMRC) Centres of Research excellence in PCOS (APP1078444) and in Women's Health in Reproductive life (APP1171592). Guideline partners, American Society for Reproductive Medicine (ASRM), Endocrine Society, European Society of Human Reproduction and Embryology (ESHRE), and European Society of Endocrinology (ESE), provided additional funding and assisted in guideline development. HT and AM are NHMRC Research Fellows. LM was funded by a Heart Foundation Future Leader and Veski Fellowship and CTT by the NHMRC Centres of Research excellence in Women's Health in Reproductive life. All disclosures of interest were declared before commencing GDG involvement and updated before all major milestones and are available alongside the PCOS Guideline (https://www.monash.edu/__data/assets/pdf_file/0009/3371292/Register-of-disclosures-of-interest.pdf).

Keywords: Consumer and community involvement; Diabetes mellitus; Evidence-based medicine; Infertility; Polycystic ovary syndrome; Public and patient involvement; Research.

PubMed Disclaimer

Conflict of interest statement

All disclosures of interest were declared before commencing GDG involvement and updated before all major milestones and are available alongside the PCOS Guideline (https://www.monash.edu/__data/assets/pdf_file/0009/3371292/Register-of-disclosures-of-interest.pdf). JL declared grants or contracts from AnshLabs, Ferring, Merck, Titus Health Care and Roche Diagnostic; consulting fees from AnshLabs, Ferring and Gedeon Richter; and participation on Advisory Board for LOCI Trial. MG declared payment or honoraria from Sharesies NZ Ltd, Women’s Health Seminar Series 2022; and support for meeting and/travel for attendance of the PCOS Guideline development meeting from the NHMRC Centre for Research Excellence in Women’s Health in Reproductive Life. TP declared grants or contracts from Research Council of Finland, Novonordisk, Sigrid Juseliud Foundation and Roche; consulting fees from Organon, Roche and Gedeon Richter; support for attending meetings and/or travels from Gedeon Richter, Ferring, and Exceltis; and leadershio role in Androgen Excess and PCOS Society and NFGO Scientific.

Figures

Fig. 1
Fig. 1
Summary of multistage process to develop International PCOS Guideline research priority roadmap.
Fig. 2
Fig. 2
Research priorities selected by women with PCOS and healthcare providers. Other research priorities included diagnosing and treating anxiety and depression (women: 19.6%, healthcare providers: 9.6%), achieving regular menstrual cycles (women: 19.3%, healthcare providers: 22.9%), understanding impacts in pregnancy (women: 11.4%, healthcare providers: 18.8%), understanding liver effects (women: 10.6%, healthcare providers: 8.1%) and understanding and improving sleep quality (women: 9.8%, healthcare providers: 3.8%). PCOS: polycystic ovary syndrome.

References

    1. Teede H.J., Tay C.T., Laven J., et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120(4):767–793. - PubMed
    1. Teede H.J., Tay C.T., Laven J., et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndromedagger. Hum Reprod. 2023;38(9):1655–1679. - PMC - PubMed
    1. Teede H.J., Tay C.T., Laven J.J.E., et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43–G64. - PubMed
    1. Teede H.J., Tay C.T., Laven J.J.E., et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. - PMC - PubMed
    1. Teede H.J., Misso M.L., Costello M.F., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol. 2018;89(3):251–268. - PMC - PubMed

LinkOut - more resources